The According to a release, the portfolio includes nearly 100 issued and pending microRNA patents that could lead to entirely new, more effective and more targeted ways to diagnose and treat prostate, ovarian, colon and lung cancers. Additionally,
These technologies, years in the making, the group said, were developed by
Just over 10 years ago, Croce was the first in the world to link small cellular molecules called microRNA to cancer. MicroRNAs are now known to play a pivotal role in the growth and spread of many kinds of cancer, and they have shown great potential for transforming the diagnosis and treatment of cancer and other diseases.
"MicroRNAs have been the subject of study by my laboratory for more than a decade, and our work and the work of others has shown that the dysregulation of these molecules plays a critical role in the development of cancer and other diseases," says Croce, who is professor and chair of molecular virology, immunology and medical genetics, the John W. Wolfe Chair in Human Cancer Genetics and a member of the OSUCCC James Molecular Biology and Cancer Genetics Program.
"This licensing agreement will help translate these discoveries into transformational changes in the diagnosis and treatment of several human cancers.
"I am also pleased that The
To further facilitate the development of microRNA therapeutic applications, the group added, Lee, professor of pharmaceutics and pharmaceutical chemistry and a member of the OSUCCC James Experimental Therapeutics Program, invented a novel and efficient platform technology to deliver the microRNA to the target of interest with minimal degradation and to prolong stability of the molecules, a historical challenge in the field of microRNA therapy.
"Nanoparticles can improve the pharmacokinetic properties of oligonucleotides, including microRNAs, and help them get into the tumor and then into the target cell," says Lee. "My lab in the
"Our goal is to support the researchers at
"Dr. Croce and Dr. Lee are genuine thought leaders in their disciplines. The technologies they and their colleagues created will truly change the diagnostic and therapeutic landscape of cancer and ultimately patient care."
((Comments on this story may be sent to firstname.lastname@example.org))
According to a release, the portfolio includes nearly 100 issued and pending microRNA patents that could lead to entirely new, more effective and more targeted ways to diagnose and treat prostate, ovarian, colon and lung cancers. Additionally,